Ignite Creation Date:
2025-12-26 @ 10:56 AM
Ignite Modification Date:
2025-12-29 @ 1:50 PM
Study NCT ID:
NCT00346008
Status:
COMPLETED
Last Update Posted:
2013-05-30
First Post:
2006-06-27
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Studying Genes to Identify Melanoma in Patients in Iceland and Their Family Members
Sponsor:
Iceland Genomics Corporation
Organization:
Study Overview
Official Title:
Genetic Epidemiologic Studies of Melanoma in Iceland
Status:
COMPLETED
Status Verified Date:
2008-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE: Studying the genes expressed in samples of blood from patients with cancer and their family members may help doctors identify biomarkers related to cancer.
PURPOSE: This clinical trial is studying genes to identify melanoma in patients in Iceland and their family members.
PURPOSE: This clinical trial is studying genes to identify melanoma in patients in Iceland and their family members.
Detailed Description:
OBJECTIVES:
* Assess the feasibility of Iceland Genomics Corporation (UVS) to identify melanoma in multiple-case families, individuals with multiple tumors, and selected additional family members in Iceland.
* Assess the feasibility of mutation detection using sequencing and HPLC.
* Determine UVS' ability to create datasets with demographic, epidemiologic and molecular data.
OUTLINE: Participants and patients undergo blood collection and complete lifestyle questionnaires. All patients and population-based controls have DNA samples sequenced for MC1R. Demographic and epidemiologic data on all study participants is collected. Sequencing of the major melanoma susceptibility genes CFDKN2A, CDK4, and MC1R is also performed.
* Assess the feasibility of Iceland Genomics Corporation (UVS) to identify melanoma in multiple-case families, individuals with multiple tumors, and selected additional family members in Iceland.
* Assess the feasibility of mutation detection using sequencing and HPLC.
* Determine UVS' ability to create datasets with demographic, epidemiologic and molecular data.
OUTLINE: Participants and patients undergo blood collection and complete lifestyle questionnaires. All patients and population-based controls have DNA samples sequenced for MC1R. Demographic and epidemiologic data on all study participants is collected. Sequencing of the major melanoma susceptibility genes CFDKN2A, CDK4, and MC1R is also performed.
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
NCT ID Aliases
| NCT ID Alias | NCT ID | View |
|---|---|---|
| None | NCT00346008 | View |